Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495704 | 1.00 | NOS2 (0.54) | NOS2NOS3NOS1CDK2GAA | |
| SCHEMBL16495995 | 0.91 | GAA (0.55) | NOS2CDK2GAARAB9AGABRA5 | |
| SCHEMBL16495994 | 0.91 | GAA (0.55) | NOS2CDK2GAARAB9AGABRA5 | |
| SCHEMBL16495422 | 0.89 | HPGDS (0.48) | NOS2CDK2GAARAB9AGABRA5 | |
| SCHEMBL16495420 | 0.89 | HPGDS (0.48) | NOS2CDK2GAARAB9AGABRA5 | |
| SCHEMBL16495907 | 0.83 | ROCK2 (0.51) | GAARAB9AGABRA5LNPEPRXFP1 | |
| SCHEMBL16495908 | 0.83 | ROCK2 (0.51) | GAARAB9AGABRA5LNPEPRXFP1 | |
| SCHEMBL6029369 | 0.78 | GAA (0.64) | GAARAB9AGABRA5LNPEPHPGDS | |
| SCHEMBL16496425 | 0.77 | HPGDS (0.63) | NPC1RXFP1HPGDSPTPN1PTPN6 | |
| SCHEMBL16495982 | 0.77 | RXFP1 (0.61) | GABRA5NPC1RXFP1PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | NOS2 655/4885NOS3 660/4885NOS1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.